Global Cancer Supportive Care Market 2017-2021 - Product Image

Global Cancer Supportive Care Market 2017-2021

  • ID: 4397224
  • Report
  • Region: Global
  • 96 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Amgen
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Helsinn Healthcare
  • Heron Therapeutics
  • Johnson &Johnson
  • MORE
About Cancer Supportive Care

Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others.

The analysts forecast the global cancer supportive care market to grow at a CAGR of 3.38% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer supportive care market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in cancer supportive care market.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Cancer Supportive Care Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Helsinn Healthcare
  • Johnson &Johnson
  • Merck
Other prominent vendors
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Heron Therapeutics
  • Kyowa Hakko Kirin
  • Novartis
  • TESARO
  • Teva Pharmaceutical Industries
Market drivers
  • Large number of side effects associated with the cancer treatment
  • For a full, detailed list, view the full report
Market challenges
  • Rising popularity of targeted therapies for the treatment of cancer in developed countries
  • For a full, detailed list, view the full report
Market trends
  • Advent of biosimilars in cancer-associated treatment
  • For a full, detailed list, view the full report
Key questions answered in this report:
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Helsinn Healthcare
  • Heron Therapeutics
  • Johnson &Johnson
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 06: Pipeline landscape

PART 07: Market segmentation therapeutic area
  • Chemotherapy-induced anemia
  • Chemotherapy-induced neutropenia
  • Cancer pain
  • CINV
  • Others
PART 08: Geographical segmentation
  • Cancer supportive care market in Americas
  • Cancer supportive care market in EMEA
  • Cancer supportive care market in APAC
PART 09: Decision framework

PART 10: Drivers and challenges
  • Market drivers
  • Market challenges
PART 11: Market trends
  • Advent of biosimilars in cancer-associated treatment
  • Outsourcing of biosimilars manufacturing activities
PART 12: Vendor landscape
  • Competitive scenario
PART 13: Key vendor analysis
  • Amgen
  • Helsinn Healthcare
  • Johnson & Johnson
  • Merck
  • Other prominent vendors
PART 14: Appendix
  • List of abbreviations
List of Exhibits
Exhibit 01: Categories of cancers
Exhibit 02: Various modes applied for treatment of cancer
Exhibit 03: Side effects of various cancer treatments
Exhibit 04: Major drug classes used as cancer supportive agents
Exhibit 05: Global cancer supportive care market snapshot
Exhibit 06: Global cancer supportive care market 2016-2021 ($ billions)
Exhibit 07: Opportunity analysis in global cancer supportive care market
Exhibit 08: Five forces analysis
Exhibit 09: Key molecules in different stages of development
Exhibit 10: Key clinical trials
Exhibit 11: Segmentation of global cancer supportive care market by therapeutic area 2016
Exhibit 12: Segmentation of global cancer supportive care market by therapeutic area 2016 and 2021
Exhibit 13: Symptoms of anemia
Exhibit 14: Types of anemia
Exhibit 15: Global cancer supportive care market for chemotherapy-induced anemia 2016-2021 ($ billions)
Exhibit 16: Types of cancers closely associated with anemia
Exhibit 17: Commonly used ESAs
Exhibit 18: Side effects associated with the usage of ESAs
Exhibit 19: Global cancer supportive care market for chemotherapy-induced neutropenia 2016-2021 ($ billions)
Exhibit 20: Types of cancer pain
Exhibit 21: Global cancer supportive care market for cancer pain 2016-2021 ($ billions)
Exhibit 22: Global cancer supportive care market for CINV 2016-2021 ($ billions)
Exhibit 23: Major drug classes used for treatment of CINV
Exhibit 24: Analysis of global CINV drugs market
Exhibit 25: Global cancer supportive care market for others 2016-2021 ($ billions)
Exhibit 26: Some of the other side effects of cancer treatment
Exhibit 27: Effect of cancer treatment leading to oral complications
Exhibit 28: Segmentation of global cancer supportive care market by geography 2016 and 2021
Exhibit 29: Segmentation of global cancer supportive care market by geography 2016-2021 ($ billions)
Exhibit 30: Market scenario in Americas
Exhibit 31: Cancer supportive care market in Americas 2016-2021 ($ billions)
Exhibit 32: Top 10 types of cancers in US 2014 (per 100,000 people)
Exhibit 33: Cancer survivors in US: Statistics and estimations 2016 and 2026
Exhibit 34: Economic and healthcare expenditure snapshot of US 2014 and 2015 ($ billions)
Exhibit 35: Economic and healthcare snapshot of Canada 2016
Exhibit 36: New cases of cancer in Canada 2016
Exhibit 37: Market scenario in EMEA
Exhibit 38: Cancer supportive care market in EMEA 2016-2021 ($ billions)
Exhibit 39: Economic and healthcare snapshot of European region 2014
Exhibit 40: Cancer death statistics in EU 2015
Exhibit 41: Market scenario in APAC
Exhibit 42: Cancer supportive care market in APAC 2016-2021 ($ billions)
Exhibit 43: Cancer facts in China 2015
Exhibit 44: Cancer cases snapshot
Exhibit 45: Estimated investment in oncology in developed and developing countries 2017
Exhibit 46: Common side effects associated with treatment of cancer in traditional methods
Exhibit 47: General side effects of radiotherapy
Exhibit 48: Support care drugs and their effects
Exhibit 49: Demographic and economic snapshot of India and China 2014 and 2016
Exhibit 50: Factors contributing to high cost of cancer drugs
Exhibit 51: Effect of high cost of cancer drugs on cancer supportive care market
Exhibit 52: Top concerns of health insurance in US
Exhibit 53: Competitive structure analysis of global cancer supportive care market 2016
Exhibit 54: Amgen: Key highlights
Exhibit 55: Amgen: Strength assessment
Exhibit 56: Amgen: Strategy assessment
Exhibit 57: Amgen: Opportunity assessment
Exhibit 58: Helsinn Healthcare: Key highlights
Exhibit 59: Helsinn Healthcare: Strength assessment
Exhibit 60: Helsinn Healthcare: Strategy assessment
Exhibit 61: Helsinn Healthcare: Opportunity assessment
Exhibit 62: Johnson & Johnson: Key highlights
Exhibit 63: Johnson & Johnson: Strength assessment
Exhibit 64: Johnson & Johnson: Strategy assessment
Exhibit 65: Johnson & Johnson: Opportunity assessment
Exhibit 66: Merck: Key highlights
Exhibit 67: Merck: Strength assessment
Exhibit 68: Merck: Strategy assessment
Exhibit 69: Merck: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Amgen
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Helsinn Healthcare
  • Heron Therapeutics
  • Johnson &Johnson
  • MORE
New Report Released: - Global Cancer Supportive Care Market 2017-2021

The author of the report recognizes the following companies as the key players in the global cancer supportive care market: Amgen, Helsinn Healthcare, Johnson &Johnson, and Merck.

Other Prominent Vendors in the market are: F. Hoffmann-La Roche, GlaxoSmithKline, Heron Therapeutics, Kyowa Hakko Kirin, Novartis, TESARO, and Teva Pharmaceutical Industries.

Commenting on the report, an analyst from the research team said: “One trend in the market is advent of biosimilars in cancer-associated treatment. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure.”

According to the report, one driver in the market is large number of side effects associated with the cancer treatment. Progress in cancer treatment has come with several challenges that go beyond a cure. Morbidity and toxicities are among the few of the biggest hurdles faced by cancer patients while going through radiation therapy or chemotherapy. A large number of side effects are associated with the treatment of cancer. These have been a major challenge for the traditional cancer treatment market (radiation and chemotherapy). The main aim of cancer treatment is to get rid of the cancer cells.

Further, the report states that one challenge in the market is rising popularity of targeted therapies for the treatment of cancer in developed countries. The increasing preference of targeted therapies instead of chemotherapy drugs will hinder the growth prospects in the market. As there is an increased need to target-specific molecules that are responsible for the growth of cancer, the vendors are focusing on the development of targeted therapies, which are highly specific than the traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with higher side effects, the researchers are extensively conducting R&D activities to understand the disease etiology better and develop novel treatments.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Amgen
  • Helsinn Healthcare
  • Johnson &Johnson
  • Merck
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Heron Therapeutics
  • Kyowa Hakko Kirin
  • Novartis
  • TESARO
  • Teva Pharmaceutical Industries
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll